Since the HARP program is in its early stages, the
publications offered on this page do not represent dissemination from
the HARP. The works below present foundational research by HARP
investigators on hemophilia A, VWD, factor VIII, inhibitor development,
obstetric bleeding, and pediatric research.
| Study Title | Authors | Journal | Year | |
|---|---|---|---|---|
| The Environmental influences on Child Health Outcomes (ECHO)-wide Cohort. | Knapp, EA; Kress, AM; Parker, CB; Page, GP, et. al. | Am J Epidemiol | 2023 | |
| Genome- wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci. | Earley, EJ; Kelly, S; Fang, F; Alencar, CS, et. al. | Br J Haematol | 2023 | |
| Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor. | Elsheikh, E; Lavin, M; Heck, LA; Larkin, N, et. al. | J Thromb Haemost | 2023 | |
| Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia. | Tran, DQ; Benson, CC; Boice, JA; Chitlur, M, et. al. | Expert Rev Hematol | 2023 | |
| The association between intrauterine exposure to opioids, tobacco, alcohol, and cannabis and length of birth hospitalization among neonates without NOWS. | Ondersma, SJ; Kress, AM; Stroustrup, A; Annett, RD, et. al. | J Perinatol | 2023 | |
| JTH in Clinic - Obstetric bleeding: VWD and other inherited bleeding disorders. | Johnsen, JM; MacKinnon, HJ | J Thromb Haemost | 2022 | |
| Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway. | Patel, SR; Lundgren, TS; Baldwin, WH; Cox, C, et. al. | Front Immunol | 2022 | |
| Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. | Roubinian, NH; Reese, SE; Qiao, H; Plimier, C, et. al. | JCI Insight | 2022 | |
| Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. | Johnsen, JM; Fletcher, SN; Dove, A; McCracken, H, et. al. | J Thromb Haemost | 2022 | |
| Sex-specific genetic modifiers identified susceptibility of cold stored red blood cells to osmotic hemolysis. | Fang, F; Hazegh, K; Mast, AE; Triulzi, DJ, et. al. | BMC Genomics | 2022 | |
| B cell-activating factor modulates the factor VIII immune response in hemophilia A. | Doshi, BS; Rana, J; Castaman, G; Shaheen, MA, et. al. | J Clin Invest | 2021 | |
| Multiple- ancestry genome-wide association study identifies 27 loci associated with measures of hemolysis following blood storage. | Page, GP; Kanias, T; Guo, YJ; Lanteri, MC, et. al. | J Clin Invest | 2021 | |
| Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status. | Batsuli, G; Greene, A; Meeks, SL; Sidonio, RF | Res Pract Thromb Haemost | 2021 | |
| The odds and implications of coinheritance of hemophilia A and B. | Karch, C; Masser-Frye, D; Limjoco, J; Ryan, SE, et. al. | Res Pract Thromb Haemost | 2020 | |
| Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century. | Arruda, VR; Doshi, BS | Mediterr J Hematol Infect Dis | 2020 | |
| Family Environment, Neurodevelopmental Risk, and the Environmental Influences on Child Health Outcomes (ECHO) Initiative: Looking Back and Moving Forward. | Bush, NR; Wakschlag, LS; LeWinn, KZ; Hertz-Picciotto, I, et. al. | Front Psychiatry | 2020 | |
| Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors. | Doshi, BS; Raffini, LJ; George, LA | J Thromb Haemost | 2020 | |
| The national blueprint for pregnancy/birth longitudinal cohorts to study factor VIII immunogenicity: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors. | Johnsen, JM; Brown, DL | Haemophilia | 2019 | |
| The national blueprint for future basic and translational research to understand factor VIII immunogenicity: NHLBI State of the Science Workshop on factor VIII inhibitors. | Meeks, SL; Herzog, RW | Haemophilia | 2019 | |
| Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. | Konkle, BA; Johnsen, JM; Wheeler, M; Watson, C, et. al. | Haemophilia | 2018 | |
| Novel approaches to hemophilia therapy: successes and challenges. | Arruda, VR; Doshi, BS; Samelson-Jones, BJ | Blood | 2017 | |
| Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. | Johnsen, JM; Fletcher, SN; Huston, H; Roberge, S, et. al. | Blood Adv | 2017 | |
| Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A. | Zerra, PE; Cox, C; Baldwin, WH; Patel, SR, et. al. | Blood | 2017 | |
| A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII. | Eubanks, J; Baldwin, WH; Markovitz, R; Parker, ET, et. al. | Blood | 2016 | |
| High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. | Batsuli, G; Deng, W; Healey, JF; Parker, ET, et. al. | Blood | 2016 | |
| Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy. | Drury-Stewart, DN; Lannert, KW; Chung, DW; Teramura, GT, et. al. | PLoS One | 2014 | |
| The diversity of the immune response to the A2 domain of human factor VIII. | Markovitz, RC; Healey, JF; Parker, ET; Meeks, SL, et. al. | Blood | 2013 | |
| Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition. | Doshi, BS; Gangadharan, B; Doering, CB; Meeks, SL | PLoS One | 2012 | |
| A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. | Meeks, SL; Cox, CL; Healey, JF; Parker, ET, et. al. | Blood | 2012 | |
| Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. | Meeks, SL; Healey, JF; Parker, ET; Barrow, RT, et. al. | Blood | 2008 | |
| Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. | Meeks, SL; Healey, JF; Parker, ET; Barrow, RT, et. al. | Blood | 2007 |